TLPH vs. NERV, INDP, VBIV, AYTU, COCP, APM, VINC, TRAW, FLGC, and NRSN
Should you be buying Talphera stock or one of its competitors? The main competitors of Talphera include Minerva Neurosciences (NERV), Indaptus Therapeutics (INDP), VBI Vaccines (VBIV), Aytu BioPharma (AYTU), Cocrystal Pharma (COCP), Aptorum Group (APM), Vincerx Pharma (VINC), Traws Pharma (TRAW), Flora Growth (FLGC), and NeuroSense Therapeutics (NRSN). These companies are all part of the "pharmaceutical preparations" industry.
Minerva Neurosciences (NASDAQ:NERV) and Talphera (NASDAQ:TLPH) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, community ranking, risk, media sentiment, analyst recommendations, earnings, valuation, dividends and institutional ownership.
Talphera's return on equity of 0.00% beat Minerva Neurosciences' return on equity.
Minerva Neurosciences has a beta of 0.27, meaning that its stock price is 73% less volatile than the S&P 500. Comparatively, Talphera has a beta of 0.46, meaning that its stock price is 54% less volatile than the S&P 500.
34.6% of Minerva Neurosciences shares are owned by institutional investors. Comparatively, 37.7% of Talphera shares are owned by institutional investors. 6.4% of Minerva Neurosciences shares are owned by insiders. Comparatively, 3.0% of Talphera shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Minerva Neurosciences received 344 more outperform votes than Talphera when rated by MarketBeat users. However, 100.00% of users gave Talphera an outperform vote while only 60.66% of users gave Minerva Neurosciences an outperform vote.
Minerva Neurosciences presently has a consensus price target of $7.00, suggesting a potential upside of 184.55%. Talphera has a consensus price target of $4.50, suggesting a potential upside of 336.89%. Given Minerva Neurosciences' stronger consensus rating and higher possible upside, analysts plainly believe Talphera is more favorable than Minerva Neurosciences.
Talphera has higher revenue and earnings than Minerva Neurosciences. Talphera is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks.
In the previous week, Minerva Neurosciences and Minerva Neurosciences both had 5 articles in the media. Talphera's average media sentiment score of 0.45 beat Minerva Neurosciences' score of 0.31 indicating that Minerva Neurosciences is being referred to more favorably in the media.
Summary
Talphera beats Minerva Neurosciences on 10 of the 15 factors compared between the two stocks.
Get Talphera News Delivered to You Automatically
Sign up to receive the latest news and ratings for TLPH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TLPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Talphera Competitors List
Related Companies and Tools
